Myoung-don K. Oh
Experienced in Infective Endocarditis

Myoung-don K. Oh

Seoul, KR 
Experienced in Infective Endocarditis
Seoul, KR 
OverviewLocationsClinical Research

Overview

Myoung-don Oh practices in Seoul, Republic of Korea. Mr. Oh is rated as an Experienced expert by MediFind in the treatment of Infective Endocarditis. His top areas of expertise are Middle East Respiratory Syndrome (MERS), Severe Acute Respiratory Syndrome (SARS), Sepsis, Thrombectomy, and Bone Marrow Transplant.

His clinical research consists of co-authoring 241 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 4 articles in the study of Infective Endocarditis.

Gender
Male

Locations

Seoul, Republic of Korea
Other Locations
Republic of Korea
Haeundae, Republic of Korea
Department Of Green Chemistry And Environmental Biotechnology, Daejeon, Republic of Korea
Busan, Republic of Korea
Songnam, Republic of Korea
Daegu, Republic of Korea

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 2 Study to Assess Dose-Response, Efficacy (Immunogenicity) and the Safety of GC1109 Administered in Multi Intramuscular Doses to Healthy Subjects
A Phase 2 Study to Assess Dose-Response, Efficacy (Immunogenicity) and the Safety of GC1109 Administered in Multi Intramuscular Doses to Healthy Subjects
Enrollment Status: Completed
Publish Date: January 04, 2023
Intervention Type: Biological
Study Phase: Phase 2
A Double-blind, Multi-center, Multi-regional, Randomized Controlled, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of CKD-314 in Hospitalized Adult Patients Diagnosed With COVID-19
A Double-blind, Multi-center, Multi-regional, Randomized Controlled, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of CKD-314 in Hospitalized Adult Patients Diagnosed With COVID-19
Enrollment Status: Unknown
Publish Date: August 02, 2021
Intervention Type: Drug
Study Drug: CKD-314+SOC
Study Phase: Phase 3
View 1 Less Clinical Trial

241 Total Publications

Immunogenicity and safety evaluation of a recombinant protective antigen anthrax vaccine (GC1109): A phase II, dose-confirmed, randomized, double-blind, placebo-controlled study.
Immunogenicity and safety evaluation of a recombinant protective antigen anthrax vaccine (GC1109): A phase II, dose-confirmed, randomized, double-blind, placebo-controlled study.
Journal: Vaccine
Published: January 21, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Oh's expertise for a condition
ConditionClose
    View All 27 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile